Cargando…
REGN-EB3: First Approval
REGN-EB3 (INMAZEB(®), Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies—atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) —that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during an Ebola outbreak in th...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799152/ https://www.ncbi.nlm.nih.gov/pubmed/33432551 http://dx.doi.org/10.1007/s40265-020-01452-3 |